alitretinoin

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hand Dermatoses

Conditions

Hand Dermatoses

Trial Timeline

Dec 1, 2004 โ†’ Sep 1, 2007

About alitretinoin

alitretinoin is a phase 3 stage product being developed by Basilea Pharmaceutica for Hand Dermatoses. The current trial status is completed. This product is registered under clinical trial identifier NCT00124475. Target conditions include Hand Dermatoses.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (5)

NCT IDPhaseStatus
NCT01407679Phase 2Terminated
NCT00519675Phase 3Completed
NCT00309621Phase 3Completed
NCT00124436Phase 3Completed
NCT00124475Phase 3Completed

Competing Products

17 competing products in Hand Dermatoses

See all competitors
ProductCompanyStageHype Score
Lebrikizumab + PlaceboEli LillyPhase 3
77
Methylprednisolone TabletJohnson & JohnsonPhase 2/3
65
ABT-981 + Placebo for ABT-981AbbViePhase 2
52
Pimecrolimus Cream 1%NovartisPhase 3
77
tocilizumab + saline solutionRochePhase 3
77
denosumab + PlaceboAmgenPhase 2
51
Dupilumab + PlaceboSanofiPhase 2
51
dupilumab + PlaceboSanofiPhase 3
76
clobetasol propionateGSK plcApproved
84
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smoothยฎ Udder Cream)BayerPhase 2
49
Ruxolitinib cream + VehicleIncytePhase 3
74
Ruxolitinib cream + VehicleIncytePhase 2
49
RuxolitinibIncytePhase 1/2
38
Ruxolitinib cream + VehicleIncytePhase 3
74
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle CreamArcutis BiotherapeuticsPhase 1/2
36
alitretinoinBasilea PharmaceuticaPhase 3
72
alitretinoinBasilea PharmaceuticaPhase 3
72